<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of diabetic polyneuropathy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of diabetic polyneuropathy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of diabetic polyneuropathy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eva L Feldman, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Involvement of the peripheral and autonomic nervous systems is the most common complication of diabetes. The duration and severity of hyperglycemia and the metabolic syndrome are the two important risk factors for the development of diabetic neuropathy in patients with type 1 or type 2 diabetes.</p><p>This topic will address the pathogenesis of diabetic polyneuropathy. Other aspects of diabetic neuropathy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5275.html" rel="external">"Epidemiology and classification of diabetic neuropathy"</a> and  <a class="medical medical_review" href="/z/d/html/5272.html" rel="external">"Screening for diabetic polyneuropathy"</a> and  <a class="medical medical_review" href="/z/d/html/5280.html" rel="external">"Management of diabetic neuropathy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Axons from motor neurons in the spinal cord relay signals to muscles, while axons from sensory neurons at the dorsal root ganglia receive signals from skin and joints. Supporting these axons presents a unique challenge, as they are frequently 20,000 times longer than their corresponding cell bodies. Schwann cells provide supporting myelin for axons in the peripheral nervous system, but most sensory axons are unmyelinated, making them more susceptible to damage than motor axons.</p><p>Distal symmetric polyneuropathy is the most common form of diabetic neuropathy [<a href="#rid1">1</a>]. The cause is a length-dependent "dying back" axonopathy, primarily involving the distal portions of the longest myelinated and unmyelinated sensory axons, with relative sparing of motor axons [<a href="#rid2">2</a>]. Though distal "dying back" is commonly seen, there is also evidence for proximal nerve dysfunction at the sensory ganglia, which may contribute to this phenomenon [<a href="#rid3">3</a>].</p><p>Distal symmetric polyneuropathy is morphologically and functionally indistinguishable from many other "metabolic" neuropathies, including uremic neuropathy and alcoholic neuropathy. However, in diabetic neuropathy, morphologic abnormalities of the vasa nervorum are present early in the course of the disease and may parallel the severity of the nerve fiber loss [<a href="#rid4">4</a>]. Thus, the morphologic characteristics of diabetic neuropathy support a vascular component, although most damage is likely secondary to metabolic impairment and loss of required energy in the distal sensory axons [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H4"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>In diabetes, a complex array of metabolic and vascular factors shift the balance between nerve fiber damage and nerve fiber repair in favor of damage [<a href="#rid2">2</a>]. This occurs in a fiber-selective pattern that preferentially affects the more vulnerable distal sensory and autonomic fibers, leading to the progressive loss of sensation that underlies the clinical manifestations of diabetic polyneuropathy.</p><p>Understanding of the pathogenesis of diabetic neuropathy has evolved from the idea that one single disrupted metabolic pathway was responsible for disease, to the realization that multiple differentially regulated pathways converge to promote mitochondrial dysfunction with bioenergetic failure and oxidative damage of axons  (<a class="graphic graphic_figure graphicRef129723" href="/z/d/graphic/129723.html" rel="external">figure 1</a>). Because mitochondria must travel from the sensory neuron along the entire length of the axon to supply axonal energy requirements, metabolic injury occurs both at the cell body and during mitochondrial trafficking, leading to bioenergetic failure, especially at the most distal portion of the axon. This results in the distal to proximal axonal loss that is the hallmark of diabetic neuropathy  (<a class="graphic graphic_figure graphicRef129368" href="/z/d/graphic/129368.html" rel="external">figure 2</a>).</p><p class="headingAnchor" id="H5"><span class="h2">Metabolism</span></p><p class="headingAnchor" id="H849836615"><span class="h3">Energy production</span><span class="headingEndMark"> — </span>Circulating glucose and lipids serve as energy sources for the peripheral nervous system. Glucose, via glycolysis and the tricarboxylic acid (TCA), and lipids, via beta-oxidation, produce two dinucleotide cofactors central to metabolism: reduced nicotinamide adenine dinucleotide (NADH) and reduced flavin adenine dinucleotide (FADH2). These cofactors are shuttled into the mitochondria as a source of cellular energy to produce adenosine triphosphate (ATP) via oxidative phosphorylation [<a href="#rid6">6</a>]. Natural byproducts of oxidative phosphorylation are reactive oxygen species (ROS), including superoxide dismutase, glutathione, and catalase. Produced in low levels, ROS are required for normal physiology with essential roles in immunity and cardiovascular tone [<a href="#rid7">7,8</a>].</p><p>People with diabetes have excess circulating glucose and lipids, which overwhelm the normal production of ATP, resulting in increased ROS production, energy failure, and loss of normal cellular function [<a href="#rid9">9</a>]. As an example, increased ROS disrupt endoplasmic reticulum function, leading to protein misfolding and cellular injury [<a href="#rid10">10</a>]. Increased ROS also directly damage mitochondria, disrupt normal cellular signaling, and produce significant cellular damage, resulting in a vicious feed-forward cycle of energy failure and loss of normal function [<a href="#rid11">11-13</a>]. These disrupted processes occur throughout all cell types in the peripheral nervous system in diabetes [<a href="#rid2">2,14</a>]. Importantly, injured mitochondria can no longer travel down the axons, and this disruption in normal mitochondrial axonal trafficking underlies the distal to proximal pattern of axonal damage observed in diabetic neuropathy [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H1458845639"><span class="h3">Other metabolic pathways</span><span class="headingEndMark"> — </span>Several other metabolic pathways have been studied in the context of diabetic neuropathy, including as potential therapeutic targets [<a href="#rid16">16,17</a>]. In light of the emerging importance of bioenergetics in the pathogenesis of diabetic neuropathy, future therapeutic efforts will need to address both energy homeostasis and specific metabolic pathway abnormalities.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polyol and hexosamine</strong> – Excess glucose is metabolized by both the polyol and hexosamine pathways. In the polyol pathway, accumulation of <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a> leads to depletion of reduced nicotinamide adenine dinucleotide phosphate (NADPH) [<a href="#rid18">18</a>]. The hexosamine pathway produces excess acetylated dinucleotides [<a href="#rid19">19</a>]. In both cases, these byproducts of energy excess lead to increased ROS, energy loss, and inflammation [<a href="#rid18">18,20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advanced glycation end products</strong> – Elevated systemic levels of glucose in diabetes lead to glycation of plasma and tissue proteins and formation of advanced glycation end products (AGEs). This nonenzymatic process forms irreversible AGEs that bind to the cell surface receptor called RAGE (receptor for AGE). Activation of RAGE increases ROS [<a href="#rid21">21</a>], promotes neural inflammation, disrupts cellular signaling, and alters normal gene expression in the peripheral nervous system, further promoting diabetic neuropathy [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Unifying mechanism</span><span class="headingEndMark"> — </span>The concept of oxidative stress provides a unifying mechanism for neural damage and for the onset and progression of diabetic neuropathy. Hyperglycemia and hyperlipidemia disrupt peripheral nervous system energy production and result in ROS, with resulting nerve injury and dysfunction. Changes in the polyol and hexosamine pathways, along with AGE formation, further promote oxidative damage.</p><p>Because different metabolic impairments are tightly interrelated, a vicious feed-forward cycle of altered metabolism, ROS accumulation, and reduced antioxidant defense occurs. This leads to peripheral nerve damage and the signs and symptoms of diabetic neuropathy  (<a class="graphic graphic_figure graphicRef129723" href="/z/d/graphic/129723.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef129368" href="/z/d/graphic/129368.html" rel="external">figure 2</a>) [<a href="#rid2">2,5,16</a>].</p><p>In support of a role for oxidative stress in the pathogenesis of peripheral neuropathy, patients with diabetes who are treated with antioxidants show clinically meaningful improvements in neuropathic symptoms and neuropathic deficits [<a href="#rid23">23-25</a>]. (See  <a class="medical medical_review" href="/z/d/html/5280.html" rel="external">"Management of diabetic neuropathy"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Role of ischemia</span><span class="headingEndMark"> — </span>Nerve ischemia was initially invoked in the pathogenesis of diabetic polyneuropathy because of morphologic evidence on sural nerve biopsies as well as the presence of thickened endoneurial blood vessel walls and vascular occlusions at autopsy [<a href="#rid4">4,26-30</a>]. Ischemia is secondary to well-documented endothelial dysfunction in diabetes, with loss of vasodilation and increased vasoconstriction [<a href="#rid31">31,32</a>].</p><p>Ischemic and metabolic factors may operate together [<a href="#rid33">33,34</a>]. Ischemia itself has metabolic consequences that may be exacerbated by insulin deficiency and hyperglycemia [<a href="#rid33">33</a>]. Inflammation, specifically acute-phase reactants and interleukins, may also play a role [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Role of nerve fiber repair</span><span class="headingEndMark"> — </span>Peripheral nerve repair is impaired in diabetes [<a href="#rid36">36,37</a>]. This complication may be due to disease-induced loss of neurotrophic peptides that normally mediate nerve repair, regeneration, and tonic maintenance. These peptides include nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, the insulin-like growth factors, and vascular endothelial growth factor [<a href="#rid36">36</a>]. Additionally, insulin functions as a neurotrophic factor to peripheral neurons, and thus loss of insulin in type 1 diabetes may compromise nerve viability and repair [<a href="#rid38">38</a>].</p><p>Studies in laboratory animals suggest that expression of nerve growth factor and other neurotrophic factors may be decreased in diabetes, which could lead to decreased repair and perhaps impaired maintenance of peripheral nerve fibers [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H839519092"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116787.html" rel="external">"Society guideline links: Neuropathy"</a>.)</p><p class="headingAnchor" id="H23021753"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15648.html" rel="external">"Patient education: Nerve damage caused by diabetes (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/1746.html" rel="external">"Patient education: Diabetic neuropathy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H185172517"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> – Distal symmetric polyneuropathy is the most common form of diabetic neuropathy. The proximate cause is a length-dependent "dying back" axonopathy, primarily involving the distal portions of the longest myelinated and unmyelinated sensory axons, with relative sparing of motor axons. (See <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – In diabetes, a complex array of metabolic, vascular, and perhaps hormonal factors shifts the balance between nerve fiber damage and nerve fiber repair in favor of the former. This occurs in a fiber-selective pattern that preferentially affects distal sensory and autonomic fibers, leading to the progressive loss of sensation that underlies the clinical manifestations of diabetic polyneuropathy. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Energy production failure</strong> – Excess circulating glucose and lipids in patients with diabetic polyneuropathy overwhelm the normal production of ATP, resulting in increased reactive oxygen species production, mitochondrial damage, energy failure, and loss of normal cellular function. (See <a class="local">'Energy production'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other metabolic pathways</strong> – Byproducts of energy excess in the polyol and hexosamine metabolic pathways also can lead to increased reactive oxygen species (ROS), energy loss, and inflammation contributing to diabetic polyneuropathy. (See <a class="local">'Other metabolic pathways'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of ischemia</strong> – Nerve ischemia has been invoked in the pathogenesis of diabetic polyneuropathy because of the presence of thickened endoneurial blood vessel walls and vascular occlusions at autopsy. This is supported by morphologic and clinical evidence. (See <a class="local">'Role of ischemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impaired nerve fiber repair</strong> – Loss of neurotrophic peptides that normally mediate nerve repair, regeneration, and tonic maintenance contribute to diabetic polyneuropathy. Additionally, insulin functions as a neurotrophic factor to peripheral neurons, and thus loss of insulin in type 1 diabetes may compromise nerve viability and repair. (See <a class="local">'Role of nerve fiber repair'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43:817.</a></li><li><a class="nounderline abstract_t">Feldman EL, Nave KA, Jensen TS, Bennett DLH. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron 2017; 93:1296.</a></li><li><a class="nounderline abstract_t">Zochodne DW. Sensory Neurodegeneration in Diabetes: Beyond Glucotoxicity. Int Rev Neurobiol 2016; 127:151.</a></li><li><a class="nounderline abstract_t">Malik RA. Pathology of human diabetic neuropathy. Handb Clin Neurol 2014; 126:249.</a></li><li><a class="nounderline abstract_t">Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers 2019; 5:41.</a></li><li><a class="nounderline abstract_t">Hinder LM, Vincent AM, Burant CF, et al. Bioenergetics in diabetic neuropathy: what we need to know. J Peripher Nerv Syst 2012; 17 Suppl 2:10.</a></li><li><a class="nounderline abstract_t">Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol 2014; 24:R453.</a></li><li><a class="nounderline abstract_t">Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol 2020; 21:363.</a></li><li><a class="nounderline abstract_t">Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, Nogueira-Machado JA. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis 2018; 9:119.</a></li><li><a class="nounderline abstract_t">O'Brien PD, Hinder LM, Sakowski SA, Feldman EL. ER stress in diabetic peripheral neuropathy: A new therapeutic target. Antioxid Redox Signal 2014; 21:621.</a></li><li><a class="nounderline abstract_t">Pinti MV, Fink GK, Hathaway QA, et al. Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis. Am J Physiol Endocrinol Metab 2019; 316:E268.</a></li><li><a class="nounderline abstract_t">Chowdhury SK, Smith DR, Fernyhough P. The role of aberrant mitochondrial bioenergetics in diabetic neuropathy. Neurobiol Dis 2013; 51:56.</a></li><li><a class="nounderline abstract_t">Savelieff MG, Callaghan BC, Feldman EL. The emerging role of dyslipidemia in diabetic microvascular complications. Curr Opin Endocrinol Diabetes Obes 2020; 27:115.</a></li><li><a class="nounderline abstract_t">Gonçalves NP, Vægter CB, Pallesen LT. Peripheral Glial Cells in the Development of Diabetic Neuropathy. Front Neurol 2018; 9:268.</a></li><li><a class="nounderline abstract_t">Rumora AE, Savelieff MG, Sakowski SA, Feldman EL. Disorders of mitochondrial dynamics in peripheral neuropathy: Clues from hereditary neuropathy and diabetes. Int Rev Neurobiol 2019; 145:127.</a></li><li><a class="nounderline abstract_t">Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012; 11:521.</a></li><li><a class="nounderline abstract_t">Quattrini L, La Motta C. Aldose reductase inhibitors: 2013-present. Expert Opin Ther Pat 2019; 29:199.</a></li><li><a class="nounderline abstract_t">Yan LJ. Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. Animal Model Exp Med 2018; 1:7.</a></li><li><a class="nounderline abstract_t">Park S, Kang HJ, Jeon JH, et al. Recent advances in the pathogenesis of microvascular complications in diabetes. Arch Pharm Res 2019; 42:252.</a></li><li><a class="nounderline abstract_t">Grewal AS, Bhardwaj S, Pandita D, et al. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases. Mini Rev Med Chem 2016; 16:120.</a></li><li><a class="nounderline abstract_t">Nowotny K, Jung T, Höhn A, et al. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 2015; 5:194.</a></li><li><a class="nounderline abstract_t">Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 2008; 14:953.</a></li><li><a class="nounderline abstract_t">Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004; 21:114.</a></li><li><a class="nounderline abstract_t">Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003; 26:770.</a></li><li><a class="nounderline abstract_t">Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29:2365.</a></li><li><a class="nounderline abstract_t">FAGERBERG SE. Diabetic neuropathy: a clinical and histological study on the significance of vascular affections. Acta Med Scand Suppl 1959; 345:1.</a></li><li><a class="nounderline abstract_t">Dyck PJ, Hansen S, Karnes J, et al. Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci U S A 1985; 82:2513.</a></li><li><a class="nounderline abstract_t">Dyck PJ, Karnes JL, O'Brien P, et al. The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia. Ann Neurol 1986; 19:440.</a></li><li><a class="nounderline abstract_t">Dyck PJ, Lais A, Karnes JL, et al. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986; 19:425.</a></li><li><a class="nounderline abstract_t">Vracko R. A comparison of the microvascular lesions in diabetes mellitus with those in normal aging. J Am Geriatr Soc 1982; 30:201.</a></li><li><a class="nounderline abstract_t">Nukada H. Ischemia and diabetic neuropathy. Handb Clin Neurol 2014; 126:469.</a></li><li><a class="nounderline abstract_t">Jamwal S, Sharma S. Vascular endothelium dysfunction: a conservative target in metabolic disorders. Inflamm Res 2018; 67:391.</a></li><li><a class="nounderline abstract_t">Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008; 120:1.</a></li><li><a class="nounderline abstract_t">Van Dam PS, Cotter MA, Bravenboer B, Cameron NE. Pathogenesis of diabetic neuropathy: focus on neurovascular mechanisms. Eur J Pharmacol 2013; 719:180.</a></li><li><a class="nounderline abstract_t">Herder C, Lankisch M, Ziegler D, et al. Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany). Diabetes Care 2009; 32:680.</a></li><li><a class="nounderline abstract_t">Kennedy JM, Zochodne DW. Impaired peripheral nerve regeneration in diabetes mellitus. J Peripher Nerv Syst 2005; 10:144.</a></li><li><a class="nounderline abstract_t">Sango K, Mizukami H, Horie H, Yagihashi S. Impaired Axonal Regeneration in Diabetes. Perspective on the Underlying Mechanism from In Vivo and In Vitro Experimental Studies. Front Endocrinol (Lausanne) 2017; 8:12.</a></li><li><a class="nounderline abstract_t">Brussee V, Cunningham FA, Zochodne DW. Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 2004; 53:1824.</a></li><li><a class="nounderline abstract_t">Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst 2004; 9:26.</a></li></ol></div><div id="topicVersionRevision">Topic 5279 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8469345" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28334605" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27133149" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sensory Neurodegeneration in Diabetes: Beyond Glucotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25410227" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pathology of human diabetic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31197153" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diabetic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22548617" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bioenergetics in diabetic neuropathy: what we need to know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24845678" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : ROS function in redox signaling and oxidative stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32231263" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reactive oxygen species (ROS) as pleiotropic physiological signalling agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29371661" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cellular death, reactive oxygen species (ROS) and diabetic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24382087" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ER stress in diabetic peripheral neuropathy: A new therapeutic target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30601700" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22446165" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The role of aberrant mitochondrial bioenergetics in diabetic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32073426" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The emerging role of dyslipidemia in diabetic microvascular complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29770116" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Peripheral Glial Cells in the Development of Diabetic Neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31208522" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Disorders of mitochondrial dynamics in peripheral neuropathy: Clues from hereditary neuropathy and diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22608666" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diabetic neuropathy: clinical manifestations and current treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30760060" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Aldose reductase inhibitors: 2013-present.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29863179" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Redox imbalance stress in diabetes mellitus: Role of the polyol pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30771210" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Recent advances in the pathogenesis of microvascular complications in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26349493" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25786107" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Advanced glycation end products and oxidative stress in type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18473845" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Role of advanced glycation end products in diabetic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984445" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610036" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17065669" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13821282" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Diabetic neuropathy: a clinical and histological study on the significance of vascular affections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3857597" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Capillary number and percentage closed in human diabetic sural nerve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3717907" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3717906" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7061790" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A comparison of the microvascular lesions in diabetes mellitus with those in normal aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25410240" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ischemia and diabetic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29372262" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Vascular endothelium dysfunction: a conservative target in metabolic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18616962" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diabetic neuropathy: mechanisms to management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23872412" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pathogenesis of diabetic neuropathy: focus on neurovascular mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131463" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15958126" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Impaired peripheral nerve regeneration in diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28203223" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Impaired Axonal Regeneration in Diabetes. Perspective on the Underlying Mechanism from In Vivo and In Vitro Experimental Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220207" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Direct insulin signaling of neurons reverses diabetic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14871451" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The role of growth factors in diabetic peripheral neuropathy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
